Back to top
Read MoreHide Full Article
In-Depth Zacks Research for the Tickers Above
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
• Acuity Brands, Inc. (AYI - Free Report) is a producer, distributor and designer of a range of lighting solutions for commercial and residential markets across several countries. The Zacks Consensus Estimate for its current year earnings has improved by 0.2% over the last 30 days.
• Banco Bradesco S.A. (BBD - Free Report) offers a range of financial and banking services and products to individual and business customers. The Zacks Consensus Estimate for its current year earnings has improved by 3.3% over the last 30 days.
• Bristol-Myers Squibb Company (BMY - Free Report) is a global specialty biopharmaceutical company with focus on discovering, developing and delivering innovative treatments for serious diseases. It has seen the Zacks Consensus Estimate for its current year earnings climb 0.1% over the last 30 days.
• Core-Mark Holding Company, Inc. is one of the largest broad-line, full-service, wholesale distributors of packaged consumer products to the convenience retail industry in North America. It has seen the Zacks Consensus Estimate for its current year earnings climb 0.6% over the last 30 days.
• Fibrocell Science, Inc. develops first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. The Zacks Consensus Estimate revision for its current year earnings was a positive 14.2% over the last 60 days.
View the entire Zacks Rank #1 List.